The effect of secukinumab treatment on hematological parameters in ankylosing spondylitis and psoriatic arthritis

OBJECTIVE: Secukinumab, a new treatment agent, selectively neutralizes interleukin (IL)-17A. It is used in the treatment of ankylosing spondylitis (AS), psoriatic arthritis (PsA), and psoriasis. It is known that the agents used in the treatment of rheumatic diseases have effects on hematological par...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Rheumatol
Autors principals: Karataş, Ahmet, Gerçek, Aybüke Nisa, Öz, Burak, Gözel, Nevzat, Pişkin Sağır, Rabia, Gür, Mustafa, Koca, Süleyman Serdar
Format: Artigo
Idioma:Inglês
Publicat: Medical Research and Education Association 2020
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7574766/
https://ncbi.nlm.nih.gov/pubmed/32910771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5152/eurjrheum.2020.20109
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars